nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—CYP3A4—type 2 diabetes mellitus	0.126	0.534	CbGaD
Naloxone—ALB—type 2 diabetes mellitus	0.11	0.466	CbGaD
Naloxone—SLCO1A2—Tolbutamide—type 2 diabetes mellitus	0.0441	0.0879	CbGbCtD
Naloxone—ALB—Gliclazide—type 2 diabetes mellitus	0.03	0.06	CbGbCtD
Naloxone—ALB—Repaglinide—type 2 diabetes mellitus	0.0282	0.0564	CbGbCtD
Naloxone—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0273	0.0545	CbGbCtD
Naloxone—SLCO1A2—Glyburide—type 2 diabetes mellitus	0.0253	0.0505	CbGbCtD
Naloxone—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0236	0.047	CbGbCtD
Naloxone—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0218	0.0436	CbGbCtD
Naloxone—ALB—Valsartan—type 2 diabetes mellitus	0.0208	0.0416	CbGbCtD
Naloxone—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0207	0.0414	CbGbCtD
Naloxone—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0197	0.0394	CbGbCtD
Naloxone—ALB—Nateglinide—type 2 diabetes mellitus	0.0194	0.0386	CbGbCtD
Naloxone—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0185	0.0369	CbGbCtD
Naloxone—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0182	0.0364	CbGbCtD
Naloxone—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.0176	0.0351	CbGbCtD
Naloxone—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.0143	0.0286	CbGbCtD
Naloxone—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0134	0.0267	CbGbCtD
Naloxone—ALB—Glyburide—type 2 diabetes mellitus	0.0131	0.0261	CbGbCtD
Naloxone—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0124	0.0248	CbGbCtD
Naloxone—ALB—Losartan—type 2 diabetes mellitus	0.012	0.0239	CbGbCtD
Naloxone—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0111	0.0221	CbGbCtD
Naloxone—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0101	0.0202	CbGbCtD
Naloxone—CYP2C8—Losartan—type 2 diabetes mellitus	0.00924	0.0184	CbGbCtD
Naloxone—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00918	0.0183	CbGbCtD
Naloxone—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00885	0.0177	CbGbCtD
Naloxone—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00801	0.016	CbGbCtD
Naloxone—ABCB1—Glyburide—type 2 diabetes mellitus	0.00684	0.0137	CbGbCtD
Naloxone—ABCB1—Losartan—type 2 diabetes mellitus	0.00626	0.0125	CbGbCtD
Naloxone—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00607	0.0121	CbGbCtD
Naloxone—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00582	0.0116	CbGbCtD
Naloxone—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00582	0.0116	CbGbCtD
Naloxone—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0055	0.011	CbGbCtD
Naloxone—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0041	0.00818	CbGbCtD
Naloxone—CYP3A4—Losartan—type 2 diabetes mellitus	0.00375	0.00748	CbGbCtD
Naloxone—CREB1—nerve—type 2 diabetes mellitus	0.00314	0.128	CbGeAlD
Naloxone—TLR4—adipose tissue—type 2 diabetes mellitus	0.00221	0.0897	CbGeAlD
Naloxone—OPRM1—nerve—type 2 diabetes mellitus	0.00169	0.0689	CbGeAlD
Naloxone—TLR4—liver—type 2 diabetes mellitus	0.00155	0.0629	CbGeAlD
Naloxone—CREB1—islet of Langerhans—type 2 diabetes mellitus	0.00152	0.0619	CbGeAlD
Naloxone—CREB1—Candesartan—Irbesartan—type 2 diabetes mellitus	0.00146	0.389	CbGdCrCtD
Naloxone—CREB1—retina—type 2 diabetes mellitus	0.0013	0.0529	CbGeAlD
Naloxone—CREB1—Candesartan—Valsartan—type 2 diabetes mellitus	0.00124	0.33	CbGdCrCtD
Naloxone—CREB1—nephron tubule—type 2 diabetes mellitus	0.00123	0.0499	CbGeAlD
Naloxone—CREB1—cardiovascular system—type 2 diabetes mellitus	0.0011	0.0448	CbGeAlD
Naloxone—CREB1—kidney—type 2 diabetes mellitus	0.00108	0.0438	CbGeAlD
Naloxone—CREB1—pancreas—type 2 diabetes mellitus	0.00107	0.0435	CbGeAlD
Naloxone—CREB1—Candesartan—Losartan—type 2 diabetes mellitus	0.00106	0.281	CbGdCrCtD
Naloxone—CREB1—cortex of kidney—type 2 diabetes mellitus	0.00105	0.0427	CbGeAlD
Naloxone—CREB1—adipose tissue—type 2 diabetes mellitus	0.000971	0.0395	CbGeAlD
Naloxone—OPRD1—kidney—type 2 diabetes mellitus	0.000851	0.0346	CbGeAlD
Naloxone—CREB1—liver—type 2 diabetes mellitus	0.000681	0.0277	CbGeAlD
Naloxone—SLCO1A2—kidney—type 2 diabetes mellitus	0.0005	0.0203	CbGeAlD
Naloxone—ESR1—cardiovascular system—type 2 diabetes mellitus	0.000433	0.0176	CbGeAlD
Naloxone—ESR1—kidney—type 2 diabetes mellitus	0.000424	0.0172	CbGeAlD
Naloxone—ESR1—adipose tissue—type 2 diabetes mellitus	0.000382	0.0155	CbGeAlD
Naloxone—Cardiac disorder—Bromocriptine—type 2 diabetes mellitus	0.00038	0.00353	CcSEcCtD
Naloxone—Nausea—Miglitol—type 2 diabetes mellitus	0.000378	0.00352	CcSEcCtD
Naloxone—Paraesthesia—Repaglinide—type 2 diabetes mellitus	0.000375	0.00349	CcSEcCtD
Naloxone—Asthenia—Tolazamide—type 2 diabetes mellitus	0.000373	0.00348	CcSEcCtD
Naloxone—Depression—Gliclazide—type 2 diabetes mellitus	0.000373	0.00347	CcSEcCtD
Naloxone—Angiopathy—Bromocriptine—type 2 diabetes mellitus	0.000371	0.00346	CcSEcCtD
Naloxone—Tremor—Glimepiride—type 2 diabetes mellitus	0.00037	0.00344	CcSEcCtD
Naloxone—Mediastinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000369	0.00343	CcSEcCtD
Naloxone—Hypertension—Glipizide—type 2 diabetes mellitus	0.000365	0.0034	CcSEcCtD
Naloxone—Nasopharyngitis—Metformin—type 2 diabetes mellitus	0.000363	0.00338	CcSEcCtD
Naloxone—Agitation—Glimepiride—type 2 diabetes mellitus	0.000363	0.00338	CcSEcCtD
Naloxone—Gastrointestinal disorder—Repaglinide—type 2 diabetes mellitus	0.00036	0.00335	CcSEcCtD
Naloxone—Sweating—Gliclazide—type 2 diabetes mellitus	0.000359	0.00334	CcSEcCtD
Naloxone—Mental disorder—Bromocriptine—type 2 diabetes mellitus	0.000358	0.00334	CcSEcCtD
Naloxone—Diarrhoea—Chlorpropamide—type 2 diabetes mellitus	0.000356	0.00331	CcSEcCtD
Naloxone—Diarrhoea—Linagliptin—type 2 diabetes mellitus	0.000352	0.00328	CcSEcCtD
Naloxone—Hypertension—Pioglitazone—type 2 diabetes mellitus	0.00035	0.00326	CcSEcCtD
Naloxone—Tension—Bromocriptine—type 2 diabetes mellitus	0.000349	0.00325	CcSEcCtD
Naloxone—CYP2C8—kidney—type 2 diabetes mellitus	0.000349	0.0142	CbGeAlD
Naloxone—Asthenia—Nateglinide—type 2 diabetes mellitus	0.000346	0.00322	CcSEcCtD
Naloxone—Nervousness—Bromocriptine—type 2 diabetes mellitus	0.000346	0.00322	CcSEcCtD
Naloxone—Nasopharyngitis—Irbesartan—type 2 diabetes mellitus	0.000343	0.00319	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Pioglitazone—type 2 diabetes mellitus	0.000343	0.00319	CcSEcCtD
Naloxone—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.000342	0.00318	CcSEcCtD
Naloxone—Convulsion—Glimepiride—type 2 diabetes mellitus	0.000342	0.00318	CcSEcCtD
Naloxone—Hypertension—Glimepiride—type 2 diabetes mellitus	0.000341	0.00317	CcSEcCtD
Naloxone—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.00034	0.00317	CcSEcCtD
Naloxone—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00034	0.00316	CcSEcCtD
Naloxone—Hypertension—Sitagliptin—type 2 diabetes mellitus	0.00034	0.00316	CcSEcCtD
Naloxone—Depression—Orlistat—type 2 diabetes mellitus	0.000339	0.00315	CcSEcCtD
Naloxone—Hyperhidrosis—Glipizide—type 2 diabetes mellitus	0.000334	0.00311	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Sitagliptin—type 2 diabetes mellitus	0.000333	0.0031	CcSEcCtD
Naloxone—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.000331	0.00308	CcSEcCtD
Naloxone—Abdominal pain—Repaglinide—type 2 diabetes mellitus	0.00033	0.00307	CcSEcCtD
Naloxone—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.00033	0.00307	CcSEcCtD
Naloxone—Agitation—Bromocriptine—type 2 diabetes mellitus	0.000327	0.00305	CcSEcCtD
Naloxone—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	0.000324	0.00302	CcSEcCtD
Naloxone—Skin disorder—Pioglitazone—type 2 diabetes mellitus	0.000321	0.00299	CcSEcCtD
Naloxone—Hyperhidrosis—Pioglitazone—type 2 diabetes mellitus	0.00032	0.00298	CcSEcCtD
Naloxone—Vomiting—Acarbose—type 2 diabetes mellitus	0.000318	0.00296	CcSEcCtD
Naloxone—SLCO1A2—liver—type 2 diabetes mellitus	0.000316	0.0129	CbGeAlD
Naloxone—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	0.000315	0.00293	CcSEcCtD
Naloxone—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.000314	0.00293	CcSEcCtD
Naloxone—ALB—liver—type 2 diabetes mellitus	0.000314	0.0128	CbGeAlD
Naloxone—Skin disorder—Sitagliptin—type 2 diabetes mellitus	0.000312	0.0029	CcSEcCtD
Naloxone—Flushing—Gliclazide—type 2 diabetes mellitus	0.000312	0.0029	CcSEcCtD
Naloxone—Hyperhidrosis—Glimepiride—type 2 diabetes mellitus	0.000311	0.0029	CcSEcCtD
Naloxone—Paraesthesia—Glipizide—type 2 diabetes mellitus	0.00031	0.00289	CcSEcCtD
Naloxone—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000309	0.00288	CcSEcCtD
Naloxone—Nausea—Tolazamide—type 2 diabetes mellitus	0.000309	0.00288	CcSEcCtD
Naloxone—Convulsion—Bromocriptine—type 2 diabetes mellitus	0.000309	0.00287	CcSEcCtD
Naloxone—Dyspnoea—Glipizide—type 2 diabetes mellitus	0.000308	0.00287	CcSEcCtD
Naloxone—Hypertension—Bromocriptine—type 2 diabetes mellitus	0.000307	0.00286	CcSEcCtD
Naloxone—Vomiting—Nateglinide—type 2 diabetes mellitus	0.000306	0.00285	CcSEcCtD
Naloxone—Tremor—Glyburide—type 2 diabetes mellitus	0.000305	0.00284	CcSEcCtD
Naloxone—Chills—Gliclazide—type 2 diabetes mellitus	0.000301	0.0028	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Bromocriptine—type 2 diabetes mellitus	0.000301	0.0028	CcSEcCtD
Naloxone—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.000298	0.00277	CcSEcCtD
Naloxone—Nausea—Acarbose—type 2 diabetes mellitus	0.000297	0.00276	CcSEcCtD
Naloxone—Pain—Glipizide—type 2 diabetes mellitus	0.000295	0.00275	CcSEcCtD
Naloxone—Dyspnoea—Pioglitazone—type 2 diabetes mellitus	0.000295	0.00274	CcSEcCtD
Naloxone—Mental disorder—Gliclazide—type 2 diabetes mellitus	0.000294	0.00274	CcSEcCtD
Naloxone—Paraesthesia—Glimepiride—type 2 diabetes mellitus	0.000289	0.00269	CcSEcCtD
Naloxone—Dyspnoea—Glimepiride—type 2 diabetes mellitus	0.000287	0.00267	CcSEcCtD
Naloxone—Tension—Gliclazide—type 2 diabetes mellitus	0.000287	0.00267	CcSEcCtD
Naloxone—Nausea—Nateglinide—type 2 diabetes mellitus	0.000286	0.00267	CcSEcCtD
Naloxone—Cardiac disorder—Valsartan—type 2 diabetes mellitus	0.000286	0.00267	CcSEcCtD
Naloxone—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.000286	0.00266	CcSEcCtD
Naloxone—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000285	0.00266	CcSEcCtD
Naloxone—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.000285	0.00265	CcSEcCtD
Naloxone—Nervousness—Gliclazide—type 2 diabetes mellitus	0.000284	0.00264	CcSEcCtD
Naloxone—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.000284	0.00264	CcSEcCtD
Naloxone—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000283	0.00263	CcSEcCtD
Naloxone—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.000282	0.00263	CcSEcCtD
Naloxone—Convulsion—Glyburide—type 2 diabetes mellitus	0.000282	0.00263	CcSEcCtD
Naloxone—Angiopathy—Valsartan—type 2 diabetes mellitus	0.00028	0.00261	CcSEcCtD
Naloxone—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.000278	0.00259	CcSEcCtD
Naloxone—Mediastinal disorder—Valsartan—type 2 diabetes mellitus	0.000278	0.00259	CcSEcCtD
Naloxone—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000277	0.00258	CcSEcCtD
Naloxone—Mediastinal disorder—Orlistat—type 2 diabetes mellitus	0.000275	0.00256	CcSEcCtD
Naloxone—Pain—Sitagliptin—type 2 diabetes mellitus	0.000275	0.00256	CcSEcCtD
Naloxone—Tremor—Gliclazide—type 2 diabetes mellitus	0.000274	0.00255	CcSEcCtD
Naloxone—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.000273	0.00254	CcSEcCtD
Naloxone—Mental disorder—Valsartan—type 2 diabetes mellitus	0.00027	0.00252	CcSEcCtD
Naloxone—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.00027	0.00251	CcSEcCtD
Naloxone—Agitation—Gliclazide—type 2 diabetes mellitus	0.000269	0.0025	CcSEcCtD
Naloxone—ESR1—liver—type 2 diabetes mellitus	0.000268	0.0109	CbGeAlD
Naloxone—Mental disorder—Orlistat—type 2 diabetes mellitus	0.000267	0.00249	CcSEcCtD
Naloxone—Sweating—Losartan—type 2 diabetes mellitus	0.000266	0.00248	CcSEcCtD
Naloxone—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000265	0.00247	CcSEcCtD
Naloxone—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	0.000261	0.00243	CcSEcCtD
Naloxone—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.000261	0.00243	CcSEcCtD
Naloxone—Flushing—Metformin—type 2 diabetes mellitus	0.000261	0.00243	CcSEcCtD
Naloxone—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000261	0.00243	CcSEcCtD
Naloxone—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000259	0.00241	CcSEcCtD
Naloxone—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	0.000257	0.00239	CcSEcCtD
Naloxone—Angiopathy—Metformin—type 2 diabetes mellitus	0.000255	0.00237	CcSEcCtD
Naloxone—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000255	0.00237	CcSEcCtD
Naloxone—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.000254	0.00236	CcSEcCtD
Naloxone—Convulsion—Gliclazide—type 2 diabetes mellitus	0.000253	0.00236	CcSEcCtD
Naloxone—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.000253	0.00236	CcSEcCtD
Naloxone—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000252	0.00235	CcSEcCtD
Naloxone—Chills—Metformin—type 2 diabetes mellitus	0.000252	0.00235	CcSEcCtD
Naloxone—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000251	0.00234	CcSEcCtD
Naloxone—Nausea—Repaglinide—type 2 diabetes mellitus	0.000248	0.00231	CcSEcCtD
Naloxone—Asthenia—Glipizide—type 2 diabetes mellitus	0.000248	0.00231	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000247	0.0023	CcSEcCtD
Naloxone—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.000246	0.00229	CcSEcCtD
Naloxone—Flushing—Irbesartan—type 2 diabetes mellitus	0.000246	0.00229	CcSEcCtD
Naloxone—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.000241	0.00224	CcSEcCtD
Naloxone—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000239	0.00222	CcSEcCtD
Naloxone—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.000239	0.00222	CcSEcCtD
Naloxone—Chills—Irbesartan—type 2 diabetes mellitus	0.000238	0.00221	CcSEcCtD
Naloxone—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000237	0.00221	CcSEcCtD
Naloxone—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000237	0.00221	CcSEcCtD
Naloxone—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000237	0.00963	CbGeAlD
Naloxone—CYP3A4—kidney—type 2 diabetes mellitus	0.000237	0.00962	CbGeAlD
Naloxone—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000236	0.0022	CcSEcCtD
Naloxone—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000234	0.00218	CcSEcCtD
Naloxone—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000234	0.00218	CcSEcCtD
Naloxone—Buprenorphine—CYP1A2—type 2 diabetes mellitus	0.000233	0.19	CrCbGaD
Naloxone—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000233	0.00217	CcSEcCtD
Naloxone—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000232	0.00216	CcSEcCtD
Naloxone—Flushing—Losartan—type 2 diabetes mellitus	0.000232	0.00216	CcSEcCtD
Naloxone—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000231	0.00215	CcSEcCtD
Naloxone—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.000231	0.00215	CcSEcCtD
Naloxone—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.00023	0.00214	CcSEcCtD
Naloxone—Convulsion—Orlistat—type 2 diabetes mellitus	0.00023	0.00214	CcSEcCtD
Naloxone—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.00023	0.00214	CcSEcCtD
Naloxone—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.00023	0.00214	CcSEcCtD
Naloxone—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000229	0.00214	CcSEcCtD
Naloxone—Tremor—Metformin—type 2 diabetes mellitus	0.000229	0.00213	CcSEcCtD
Naloxone—Sweating—Ramipril—type 2 diabetes mellitus	0.000228	0.00213	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000227	0.00211	CcSEcCtD
Naloxone—Tension—Irbesartan—type 2 diabetes mellitus	0.000226	0.00211	CcSEcCtD
Naloxone—Angiopathy—Losartan—type 2 diabetes mellitus	0.000226	0.00211	CcSEcCtD
Naloxone—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000226	0.00211	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000224	0.00209	CcSEcCtD
Naloxone—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000224	0.00209	CcSEcCtD
Naloxone—CYP2C8—liver—type 2 diabetes mellitus	0.000221	0.00898	CbGeAlD
Naloxone—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.00022	0.00205	CcSEcCtD
Naloxone—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.00022	0.00205	CcSEcCtD
Naloxone—Vomiting—Glipizide—type 2 diabetes mellitus	0.000219	0.00204	CcSEcCtD
Naloxone—Tremor—Irbesartan—type 2 diabetes mellitus	0.000216	0.00201	CcSEcCtD
Naloxone—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000215	0.002	CcSEcCtD
Naloxone—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000214	0.00199	CcSEcCtD
Naloxone—Tension—Losartan—type 2 diabetes mellitus	0.000213	0.00198	CcSEcCtD
Naloxone—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000213	0.00198	CcSEcCtD
Naloxone—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000213	0.00198	CcSEcCtD
Naloxone—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000212	0.00198	CcSEcCtD
Naloxone—Agitation—Irbesartan—type 2 diabetes mellitus	0.000212	0.00197	CcSEcCtD
Naloxone—Hypertension—Metformin—type 2 diabetes mellitus	0.000211	0.00197	CcSEcCtD
Naloxone—Nervousness—Losartan—type 2 diabetes mellitus	0.000211	0.00196	CcSEcCtD
Naloxone—Skin disorder—Orlistat—type 2 diabetes mellitus	0.00021	0.00196	CcSEcCtD
Naloxone—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.00021	0.00196	CcSEcCtD
Naloxone—Oxymorphone—CYP3A4—type 2 diabetes mellitus	0.00021	0.171	CrCbGaD
Naloxone—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000209	0.00195	CcSEcCtD
Naloxone—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000209	0.00194	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000207	0.00192	CcSEcCtD
Naloxone—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000206	0.00192	CcSEcCtD
Naloxone—Nausea—Glipizide—type 2 diabetes mellitus	0.000205	0.00191	CcSEcCtD
Naloxone—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000205	0.00191	CcSEcCtD
Naloxone—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000204	0.0019	CcSEcCtD
Naloxone—Pain—Gliclazide—type 2 diabetes mellitus	0.000204	0.0019	CcSEcCtD
Naloxone—Tremor—Losartan—type 2 diabetes mellitus	0.000203	0.00189	CcSEcCtD
Naloxone—ABCB1—retina—type 2 diabetes mellitus	0.000202	0.00823	CbGeAlD
Naloxone—Agitation—Losartan—type 2 diabetes mellitus	0.0002	0.00186	CcSEcCtD
Naloxone—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000199	0.00185	CcSEcCtD
Naloxone—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000199	0.00185	CcSEcCtD
Naloxone—Flushing—Ramipril—type 2 diabetes mellitus	0.000199	0.00185	CcSEcCtD
Naloxone—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000197	0.00183	CcSEcCtD
Naloxone—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000196	0.00182	CcSEcCtD
Naloxone—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000195	0.00182	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000195	0.00182	CcSEcCtD
Naloxone—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000194	0.00181	CcSEcCtD
Naloxone—Skin disorder—Metformin—type 2 diabetes mellitus	0.000194	0.0018	CcSEcCtD
Naloxone—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000193	0.0018	CcSEcCtD
Naloxone—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000193	0.00179	CcSEcCtD
Naloxone—Nausea—Glimepiride—type 2 diabetes mellitus	0.000191	0.00178	CcSEcCtD
Naloxone—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000191	0.00178	CcSEcCtD
Naloxone—Asthenia—Glyburide—type 2 diabetes mellitus	0.000191	0.00177	CcSEcCtD
Naloxone—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000191	0.00775	CbGeAlD
Naloxone—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000189	0.00176	CcSEcCtD
Naloxone—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000189	0.00176	CcSEcCtD
Naloxone—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000189	0.00176	CcSEcCtD
Naloxone—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000187	0.00174	CcSEcCtD
Naloxone—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000187	0.00174	CcSEcCtD
Naloxone—Pain—Orlistat—type 2 diabetes mellitus	0.000185	0.00172	CcSEcCtD
Naloxone—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000185	0.00172	CcSEcCtD
Naloxone—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000185	0.00172	CcSEcCtD
Naloxone—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000184	0.00171	CcSEcCtD
Naloxone—Hydrocodone—CYP3A4—type 2 diabetes mellitus	0.000183	0.149	CrCbGaD
Naloxone—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000183	0.0017	CcSEcCtD
Naloxone—Tension—Ramipril—type 2 diabetes mellitus	0.000183	0.0017	CcSEcCtD
Naloxone—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000182	0.0017	CcSEcCtD
Naloxone—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000182	0.00169	CcSEcCtD
Naloxone—Nervousness—Ramipril—type 2 diabetes mellitus	0.000181	0.00168	CcSEcCtD
Naloxone—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000179	0.00167	CcSEcCtD
Naloxone—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000178	0.00166	CcSEcCtD
Naloxone—Tremor—Ramipril—type 2 diabetes mellitus	0.000174	0.00162	CcSEcCtD
Naloxone—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000174	0.00162	CcSEcCtD
Naloxone—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000173	0.00161	CcSEcCtD
Naloxone—Tachycardia—Losartan—type 2 diabetes mellitus	0.000173	0.00161	CcSEcCtD
Naloxone—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000173	0.00161	CcSEcCtD
Naloxone—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000172	0.0016	CcSEcCtD
Naloxone—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000171	0.0016	CcSEcCtD
Naloxone—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000171	0.00159	CcSEcCtD
Naloxone—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000171	0.00159	CcSEcCtD
Naloxone—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000171	0.00159	CcSEcCtD
Naloxone—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000171	0.00696	CbGeAlD
Naloxone—Agitation—Ramipril—type 2 diabetes mellitus	0.000171	0.00159	CcSEcCtD
Naloxone—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000169	0.00157	CcSEcCtD
Naloxone—Vomiting—Glyburide—type 2 diabetes mellitus	0.000169	0.00157	CcSEcCtD
Naloxone—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000168	0.00156	CcSEcCtD
Naloxone—ABCB1—kidney—type 2 diabetes mellitus	0.000167	0.00681	CbGeAlD
Naloxone—Oxycodone—CYP3A4—type 2 diabetes mellitus	0.000167	0.136	CrCbGaD
Naloxone—ABCB1—pancreas—type 2 diabetes mellitus	0.000166	0.00677	CbGeAlD
Naloxone—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000163	0.00152	CcSEcCtD
Naloxone—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000163	0.00663	CbGeAlD
Naloxone—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000163	0.00151	CcSEcCtD
Naloxone—Convulsion—Ramipril—type 2 diabetes mellitus	0.000161	0.0015	CcSEcCtD
Naloxone—Pain—Irbesartan—type 2 diabetes mellitus	0.000161	0.0015	CcSEcCtD
Naloxone—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000159	0.00148	CcSEcCtD
Naloxone—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000158	0.00147	CcSEcCtD
Naloxone—Nausea—Glyburide—type 2 diabetes mellitus	0.000158	0.00147	CcSEcCtD
Naloxone—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000158	0.00147	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000157	0.00147	CcSEcCtD
Naloxone—Asthenia—Valsartan—type 2 diabetes mellitus	0.000157	0.00146	CcSEcCtD
Naloxone—Asthenia—Orlistat—type 2 diabetes mellitus	0.000155	0.00145	CcSEcCtD
Naloxone—Buprenorphine—CYP3A4—type 2 diabetes mellitus	0.000154	0.125	CrCbGaD
Naloxone—Hydromorphone—CYP3A4—type 2 diabetes mellitus	0.000152	0.124	CrCbGaD
Naloxone—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000152	0.00141	CcSEcCtD
Naloxone—Pain—Losartan—type 2 diabetes mellitus	0.000152	0.00141	CcSEcCtD
Naloxone—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000151	0.00614	CbGeAlD
Naloxone—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00015	0.0014	CcSEcCtD
Naloxone—CYP3A4—liver—type 2 diabetes mellitus	0.00015	0.00608	CbGeAlD
Naloxone—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000149	0.00139	CcSEcCtD
Naloxone—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000149	0.00139	CcSEcCtD
Naloxone—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000149	0.00139	CcSEcCtD
Naloxone—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000148	0.00138	CcSEcCtD
Naloxone—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000148	0.00138	CcSEcCtD
Naloxone—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000148	0.00137	CcSEcCtD
Naloxone—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000147	0.00137	CcSEcCtD
Naloxone—Asthenia—Metformin—type 2 diabetes mellitus	0.000143	0.00133	CcSEcCtD
Naloxone—Nausea—Gliclazide—type 2 diabetes mellitus	0.000142	0.00132	CcSEcCtD
Naloxone—Abdominal pain—Losartan—type 2 diabetes mellitus	0.00014	0.0013	CcSEcCtD
Naloxone—Body temperature increased—Losartan—type 2 diabetes mellitus	0.00014	0.0013	CcSEcCtD
Naloxone—Vomiting—Valsartan—type 2 diabetes mellitus	0.000139	0.0013	CcSEcCtD
Naloxone—Vomiting—Orlistat—type 2 diabetes mellitus	0.000138	0.00128	CcSEcCtD
Naloxone—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000137	0.00127	CcSEcCtD
Naloxone—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000136	0.00127	CcSEcCtD
Naloxone—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000136	0.00126	CcSEcCtD
Naloxone—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000135	0.00126	CcSEcCtD
Naloxone—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000131	0.00122	CcSEcCtD
Naloxone—Nausea—Valsartan—type 2 diabetes mellitus	0.00013	0.00121	CcSEcCtD
Naloxone—Morphine—CYP3A4—type 2 diabetes mellitus	0.000129	0.105	CrCbGaD
Naloxone—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000129	0.0012	CcSEcCtD
Naloxone—Nausea—Orlistat—type 2 diabetes mellitus	0.000129	0.0012	CcSEcCtD
Naloxone—Asthenia—Losartan—type 2 diabetes mellitus	0.000127	0.00118	CcSEcCtD
Naloxone—Vomiting—Metformin—type 2 diabetes mellitus	0.000127	0.00118	CcSEcCtD
Naloxone—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000121	0.00113	CcSEcCtD
Naloxone—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.00012	0.00112	CcSEcCtD
Naloxone—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.00012	0.00112	CcSEcCtD
Naloxone—Vomiting—Irbesartan—type 2 diabetes mellitus	0.00012	0.00111	CcSEcCtD
Naloxone—Nausea—Metformin—type 2 diabetes mellitus	0.000119	0.0011	CcSEcCtD
Naloxone—Vomiting—Losartan—type 2 diabetes mellitus	0.000113	0.00105	CcSEcCtD
Naloxone—Nausea—Irbesartan—type 2 diabetes mellitus	0.000112	0.00104	CcSEcCtD
Naloxone—Asthenia—Ramipril—type 2 diabetes mellitus	0.000109	0.00102	CcSEcCtD
Naloxone—ABCB1—liver—type 2 diabetes mellitus	0.000106	0.00431	CbGeAlD
Naloxone—Nausea—Losartan—type 2 diabetes mellitus	0.000105	0.00098	CcSEcCtD
Naloxone—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000104	0.000968	CcSEcCtD
Naloxone—Vomiting—Ramipril—type 2 diabetes mellitus	9.66e-05	0.0009	CcSEcCtD
Naloxone—Nausea—Ramipril—type 2 diabetes mellitus	9.03e-05	0.00084	CcSEcCtD
Naloxone—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	3.72e-06	2.94e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	3.72e-06	2.94e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—NOS3—type 2 diabetes mellitus	3.71e-06	2.93e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	3.71e-06	2.93e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GCG—type 2 diabetes mellitus	3.7e-06	2.93e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—SLC2A4—type 2 diabetes mellitus	3.7e-06	2.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.69e-06	2.92e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.69e-06	2.92e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.68e-06	2.91e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GCG—type 2 diabetes mellitus	3.68e-06	2.91e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	3.68e-06	2.91e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.68e-06	2.91e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	3.65e-06	2.88e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—TGFB1—type 2 diabetes mellitus	3.62e-06	2.86e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	3.62e-06	2.86e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.61e-06	2.85e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—C3—type 2 diabetes mellitus	3.6e-06	2.85e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.6e-06	2.84e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.56e-06	2.82e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	3.55e-06	2.81e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—type 2 diabetes mellitus	3.55e-06	2.81e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	3.54e-06	2.8e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	3.54e-06	2.8e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.51e-06	2.77e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.43e-06	2.71e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.42e-06	2.71e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AGT—type 2 diabetes mellitus	3.42e-06	2.7e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	3.4e-06	2.69e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—type 2 diabetes mellitus	3.39e-06	2.68e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.37e-06	2.67e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.36e-06	2.66e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	3.36e-06	2.66e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	3.36e-06	2.66e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—LEP—type 2 diabetes mellitus	3.35e-06	2.65e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOE—type 2 diabetes mellitus	3.35e-06	2.65e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.35e-06	2.65e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.35e-06	2.65e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	3.33e-06	2.63e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.31e-06	2.62e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SRC—type 2 diabetes mellitus	3.31e-06	2.61e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	3.28e-06	2.59e-05	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.27e-06	2.59e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.25e-06	2.57e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.24e-06	2.56e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.23e-06	2.56e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—INS—type 2 diabetes mellitus	3.23e-06	2.55e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	3.22e-06	2.55e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	3.22e-06	2.55e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.22e-06	2.55e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	3.22e-06	2.55e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	3.21e-06	2.54e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	3.21e-06	2.54e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	3.21e-06	2.54e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	3.21e-06	2.54e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.19e-06	2.52e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GNB3—type 2 diabetes mellitus	3.19e-06	2.52e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.18e-06	2.51e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HMOX1—type 2 diabetes mellitus	3.17e-06	2.51e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.17e-06	2.51e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GNB3—type 2 diabetes mellitus	3.17e-06	2.51e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.16e-06	2.5e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	3.16e-06	2.5e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.15e-06	2.49e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAT—type 2 diabetes mellitus	3.13e-06	2.48e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.12e-06	2.47e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.12e-06	2.47e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAT—type 2 diabetes mellitus	3.11e-06	2.46e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.11e-06	2.46e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	3.08e-06	2.44e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.07e-06	2.43e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.06e-06	2.42e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.04e-06	2.41e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOB—type 2 diabetes mellitus	3.04e-06	2.4e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.03e-06	2.4e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOB—type 2 diabetes mellitus	3.02e-06	2.39e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.99e-06	2.36e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.98e-06	2.36e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.97e-06	2.35e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.97e-06	2.34e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—type 2 diabetes mellitus	2.96e-06	2.34e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	2.96e-06	2.34e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—type 2 diabetes mellitus	2.95e-06	2.34e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	2.94e-06	2.33e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	2.9e-06	2.3e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—LPL—type 2 diabetes mellitus	2.89e-06	2.28e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.87e-06	2.27e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	2.86e-06	2.27e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—INS—type 2 diabetes mellitus	2.86e-06	2.26e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.84e-06	2.25e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	2.84e-06	2.25e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.83e-06	2.24e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	2.83e-06	2.24e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.83e-06	2.24e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.83e-06	2.24e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	2.83e-06	2.23e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.83e-06	2.23e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.83e-06	2.23e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GPX1—type 2 diabetes mellitus	2.82e-06	2.23e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.82e-06	2.23e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	2.78e-06	2.2e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.78e-06	2.2e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.77e-06	2.19e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.77e-06	2.19e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.77e-06	2.19e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.76e-06	2.18e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	2.76e-06	2.18e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.75e-06	2.18e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CD36—type 2 diabetes mellitus	2.74e-06	2.17e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.73e-06	2.16e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—type 2 diabetes mellitus	2.73e-06	2.16e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—AKT1—type 2 diabetes mellitus	2.72e-06	2.15e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	2.72e-06	2.15e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	2.71e-06	2.14e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.69e-06	2.12e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.67e-06	2.11e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.66e-06	2.11e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.66e-06	2.1e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	2.65e-06	2.09e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.63e-06	2.08e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.62e-06	2.07e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.62e-06	2.07e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	2.61e-06	2.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.61e-06	2.06e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	2.6e-06	2.05e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.58e-06	2.04e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.57e-06	2.03e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	2.56e-06	2.03e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.55e-06	2.02e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.55e-06	2.02e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.55e-06	2.02e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARA—type 2 diabetes mellitus	2.55e-06	2.02e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.54e-06	2.01e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.53e-06	2e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.53e-06	2e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.53e-06	2e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—AKT1—type 2 diabetes mellitus	2.52e-06	1.99e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.51e-06	1.98e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.51e-06	1.98e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.49e-06	1.97e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.48e-06	1.96e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	2.48e-06	1.96e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.48e-06	1.96e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.48e-06	1.96e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	2.48e-06	1.96e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—AGT—type 2 diabetes mellitus	2.47e-06	1.95e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	2.47e-06	1.95e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.46e-06	1.95e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	2.44e-06	1.93e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	2.43e-06	1.92e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CALM1—type 2 diabetes mellitus	2.43e-06	1.92e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.43e-06	1.92e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOE—type 2 diabetes mellitus	2.42e-06	1.91e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.41e-06	1.91e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	2.41e-06	1.9e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.4e-06	1.9e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	2.4e-06	1.9e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOA1—type 2 diabetes mellitus	2.39e-06	1.89e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.39e-06	1.89e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.37e-06	1.88e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.36e-06	1.87e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.29e-06	1.81e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.29e-06	1.81e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.29e-06	1.81e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.28e-06	1.8e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.27e-06	1.8e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.25e-06	1.78e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.25e-06	1.78e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.23e-06	1.77e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.23e-06	1.76e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.21e-06	1.75e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.2e-06	1.74e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.18e-06	1.72e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.17e-06	1.72e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	2.16e-06	1.71e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.13e-06	1.68e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	2.13e-06	1.68e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	2.12e-06	1.68e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	2.12e-06	1.68e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARG—type 2 diabetes mellitus	2.11e-06	1.67e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	2.1e-06	1.66e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.09e-06	1.66e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.09e-06	1.66e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	2.08e-06	1.64e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.07e-06	1.64e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.07e-06	1.64e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—INS—type 2 diabetes mellitus	2.07e-06	1.63e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	2.06e-06	1.62e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.04e-06	1.61e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.01e-06	1.59e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.99e-06	1.58e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.99e-06	1.57e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.99e-06	1.57e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.91e-06	1.51e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	1.91e-06	1.51e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.9e-06	1.5e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.87e-06	1.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.86e-06	1.47e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.85e-06	1.46e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.84e-06	1.45e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	1.82e-06	1.44e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	1.82e-06	1.44e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	1.81e-06	1.43e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NOS3—type 2 diabetes mellitus	1.81e-06	1.43e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.81e-06	1.43e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.81e-06	1.43e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—AKT1—type 2 diabetes mellitus	1.77e-06	1.4e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.76e-06	1.39e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.76e-06	1.39e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.71e-06	1.35e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.71e-06	1.35e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—AKT1—type 2 diabetes mellitus	1.71e-06	1.35e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.7e-06	1.35e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.68e-06	1.33e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.67e-06	1.32e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	1.67e-06	1.32e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.66e-06	1.31e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.66e-06	1.31e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	1.66e-06	1.31e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.63e-06	1.29e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.63e-06	1.29e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.59e-06	1.26e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.59e-06	1.26e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.59e-06	1.26e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.56e-06	1.23e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.54e-06	1.22e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.53e-06	1.21e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.52e-06	1.2e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.48e-06	1.17e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.46e-06	1.16e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.45e-06	1.15e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.41e-06	1.12e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.4e-06	1.11e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.38e-06	1.09e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.33e-06	1.05e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.31e-06	1.04e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.31e-06	1.03e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.3e-06	1.03e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.29e-06	1.02e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.25e-06	9.89e-06	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.15e-06	9.12e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.14e-06	9e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.12e-06	8.82e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.02e-06	8.09e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	9.79e-07	7.74e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	9.79e-07	7.74e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	8.95e-07	7.08e-06	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	8.38e-07	6.63e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—AKT1—type 2 diabetes mellitus	8.33e-07	6.59e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	7.3e-07	5.77e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	4.5e-07	3.56e-06	CbGpPWpGaD
